Chiome Bioscience is an outsourced company of RIKEN. The AdLib technology allows the rapid production of antibodies in vitro using a gene conversion mechanism in cells derived from chickens. The system enables the creation of otherwise difficult-to-make antibodies with unlimited diversity Fujirebio will use the technology to stimulate antibody production against haptens.
RIKEN news release, July 8, 2013
Chiome Bioscience licenses AdLib antibody generation technology to Fujirebio